---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-25-000108"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:38:02.132834+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q3 revenue $73.5M (+8%), net income $31.6M; LUPKYNIS sales up 27% YoY, FY guidance raised

## Summary
- Q3 2025 net product sales of LUPKYNIS $70.6M, up 27% YoY; 9-month $197.2M, up 24%.
- Diluted EPS $0.23 (Q3), up 130% YoY; net income $31.6M, up 119%.
- FY 2025 net product sales guidance raised to $265-270M from $250-260M; total revenue guidance raised to $275-280M.
- Cash from operating activities $44.5M in Q3, up 162% YoY; cash position $351.8M.
- Positive Phase 1 results for aritinercept (BAFF/APRIL inhibitor); clinical studies in two autoimmune diseases planned by end of 2025.

## SEC filing metadata
- accession: 0001600620-25-000108
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062025000108/0001600620-25-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062025000108/auph-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-25-000108
- JSON: https://secwatch.observer/filing/0001600620-25-000108.json
- Plain text: https://secwatch.observer/filing/0001600620-25-000108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.